- Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering
- Robust and sustainable treatment effects support at least bi-annual dosing regimen
- Best-in-class potential of novel PCSK9 siRNA RN0191 supports further development as single agent or combination to further reduce atherosclerosis cardiovascular risk
SHANGHAI, China I November 17, 2024 I Rona Therapeutics, a leader in innovative RNA-based therapies, today presented positive results from the Phase 1 clinical trial of RN0191 at the American Heart Association’s (AHA) Annual Scientific Sessions in Chicago, IL, November 16th, 2024. RN0191 is a proprietary GalNAc conjugated PCSK9 siRNA designed to significantly lower low-density lipoprotein cholesterol (LDL-C) and other lipid parameters.
The Ph1 study was a randomized, single-dose ascending, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in healthy subjects with elevated LDL-C. The demographics included adults aged 18 to 60 years, spanning a BMI range of 19-30 kg/m2. All results are based on data in the database as of Oct. 14, 2024. A total of 32 subjects were randomized and treated with RN0191 from 60mg to 600mg, respectively. The baseline LDL-C mean level was ranging from 110-130 mg/dL.
After a single-dose subcutaneous injection, RN0191 showed a favorable safety profile with no serious adverse events and only mild, transient adverse events reported across all dose- levels. Dose-dependent, significant and durable changes in PCSK9, LDL-C and other lipid parameters were observed (see table below).
- Mean maximum reduction of PCSK9 >85% and LDL-C >55% have been achieved. Significant and durable LDL-C reduction is achieved up to 42% through Day180, supporting a bi-annual dosing regimen for future development
- Significant lowering of ApoB, Lp(a), non-HDL-C and total cholesterol are also noted
- Remarkable treatment effects with reduction of PCSK9, LDL-C and the other lipid parameters maintained to 6 months.
| Table. Percentage change from baseline of PCSK9 and LDL-C level after single dose of RN0191 | |||||
| Placebo | 60mg | 200mg | 400mg | 600mg | |
| PCSK9 | |||||
| Mean Maximum Change (%) | -10 % | -64 % | -79 % | -86 % | -87 % |
| (Days post injection) | (8) | (15) | (29) | (22) | (57) |
| Mean Change (%), Day 85 | -4 % | -33 % | -69 % | -79 % | -83 % |
| Individual Maximum Change (%) | -50 % | -81 % | -87 % | -91 % | -95 % |
| LDL-C | |||||
| Mean Maximum Change (%) | -6 % | -23 % | -48 % | -56 % | -51 % |
| (Days post injection) | (85) | (57) | (29) | (71) | (22) |
| Mean Change (%), Day 85 | -6 % | -20 % | -36 % | -47 % | -45 % |
| Individual Maximum Change (%) | -20 % | -63 % | -61 % | -71 % | -74 % |
Stella Shi, CEO of Rona Therapeutics, shared, “We are thrilled to report that RN0191 has demonstrated best-in-class PCSK9 siRNA potential. These results highlight RN0191’s potential as a transformative siRNA therapy for global patients with elevated LDL-C, a major risk factor for atherosclerotic cardiovascular disease either as single agent therapy or as combinatory backbone to improve cardiovascular outcome. “
About Rona Therapeutics
Rona Therapeutics is a global leader in nucleic acid innovative drug platform company, specializing in the treatment of metabolic diseases and neurological diseases. Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, and MASH. In addition, Rona Therapeutics is unlocking potential of extra-hepatic delivery for neurological disorders and adipose/muscle delivery or various metabolic syndromes.
For Further information,
Please visit: www.ronatherapeutics.com or contact: BD@ronatherapeutics.com
SOURCE: Rona Therapeutics
